Yale study adds to evidence of diabetes drug link to heart problems
(Yale School of Public Health) A new study published by The BMJ adds to evidence that rosiglitazone -- a drug used to treat type 2 diabetes -- is associated with increased risk of heart problems, especially heart failure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2020 Category: International Medicine & Public Health Source Type: news

Diabetes drug may increase risk of cardiovascular complications
According to a study published inThe BMJ, Rosiglitazone, a drug used to treat type 2 diabetes, may increase the risk of cardiovascular complications.Medical News Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 7, 2020 Category: Endocrinology Source Type: news

Meta-Analyses Link Rosiglitazone to Increased Cardiovascular Risk
THURSDAY, Feb. 6, 2020 -- Rosiglitazone seems to be associated with an increased cardiovascular risk, particularly heart failure, according to data from a systematic review and meta-analyses published online Feb. 5 in The BMJ. Joshua D. Wallach,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2020 Category: Pharmaceuticals Source Type: news

Largest ever evaluation of the cardiovascular risk of rosiglitazone published
Analysis of raw individual patient level data gives more accurate picture of drug ’s link to heart problems Related items fromOnMedica People on statins at greater risk of skin infections and diabetes Adding insulin to metformin linked to higher mortality Vitamin D does not reduce kidney damage in type 2 diabetes Raised risk of MI and mortality when starting sulfonylurea Use of DPP-4 inhibitors associated with increased risk of IBD (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 6, 2020 Category: UK Health Source Type: news

rosiglitazone (Avandia)
Title: rosiglitazone (Avandia)Category: MedicationsCreated: 11/28/1999 12:00:00 AMLast Editorial Review: 11/15/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 15, 2019 Category: Endocrinology Source Type: news

People on statins at greater risk of skin infections and diabetes
Monitor blood glucose levels of patients predisposed to diabetes, and be mindful of possible raised SSTI risks Related items fromOnMedica Use of DPP-4 inhibitors associated with increased risk of IBD UK research reveals racial inequalities in diabetes care Regulators suspend Avandia over safety concerns Daily aspirin use linked to major bleeding Statins linked to raised diabetes risk, study suggests (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 10, 2019 Category: UK Health Source Type: news

Polycystic Ovary Syndrome Awareness Month
September is   Polycystic Ovary Syndrome Awareness Month and is an excellent time to focus on the latest Cochrane evidence.Polycystic ovary syndrome (PCOS) is a very common condition affecting 8% to 13% of women. Being overweight worsens all clinical features of PCOS. These clinical features include reproductive issues such as reduced frequency of ovulation and irregular menstrual cycles, reduced fertility, polycystic ovaries onultrasound and high levels of male hormones such as testosterone, which can cause unwanted facial or body hair growth and acne. PCOS is also associated with metabolic features, withrisk factors...
Source: Cochrane News and Events - September 3, 2019 Category: Information Technology Authors: Muriah Umoquit Source Type: news

FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines
The U.S. Food and Drug Administration (FDA) has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and generics, do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines metformin and sulfonylurea. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines
[12-16-2015] The U.S. Food and Drug Administration (FDA) is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 19, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients
[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 19, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Diabetes drug may help to treat breast cancer
Research, published inCancer Cell, suggests that the diabetes drug rosiglitazone, combined with trametinib, could treat breast cancer by turning cancerous cells into fat cells. Science Alert (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 15, 2019 Category: Endocrinology Source Type: news

Genetics may predict diabetes drug side-effects
Research, published inCell Stem Cell, suggests that genetic variations in a patient’s fat cells can determine if the diabetes drug, rosiglitazone, will have unwanted side-effects. Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 11, 2019 Category: Endocrinology Source Type: news

Early age type 1 diabetes linked to shorter life expectancy than later age diagnosis
Consider earlier and wider use of preventive treatment, researchers urge Related items fromOnMedica Too few women take part in many CVD clinical trials Children risking heart health through unhealthy lifestyles Hereditary heart and diabetes problems raise risk for children Regulators suspend Avandia over safety concerns Fat children have high cardiovascular risks as teens (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 10, 2018 Category: UK Health Source Type: news

Raised risk of MI and mortality when starting sulfonylurea
Continuing metformin when introducing sulfonylureas in type 2 diabetes safer than switching Related items fromOnMedica Sugar not saturated fat is the major issue for CVD Experts query risks of pioglitazone Regulators suspend Avandia over safety concerns Daily aspirin use linked to major bleeding Use of DPP-4 inhibitors associated with increased risk of IBD (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 19, 2018 Category: UK Health Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: FDA requiere que se eliminen ciertas restricciones al recetar y dispensar medicamentos para la diabetes que contienen rosiglitazona
El 25 de noviembre, 2013, La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) ha determinado que datos recientes sobre medicamentos que contienen rosiglitazona, como Avandia, Avandamet, Avandaryl y versiones genéricas, no indican un riesgo mayor de ataque al corazón en comparación con los med icamentos estándar metformina y sulfonilurea para la diabetes de tipo 2. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients
[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

Jamaican weed stabilizes blood sugar
It was pouring rain. I could barely see as I drove up the winding mountains. But I would not be deterred from my mission. I was on my way to finally meet Jamaica’s last living Maroon healer, Ivey Harris. I finally arrived at her secluded mountain home and she met me with open arms… and an umbrella. After the rain let up, she showed me around her home. Her yard is like an all-natural pharmacy. And she’s a walking herbal encyclopedia. One of my favorites was a Jamaican vine with weird-looking warty green fruit. Most people in the U.S. would call it a weed. Today, I grow it in my backyard here in South F...
Source: Al Sears, MD Natural Remedies - December 7, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Health Avandia blood sugar diabetes diabetics drug glucose high-carb insulin Source Type: news

TSRI researchers explore ways that a drug like Avandia can be made safer
(Scripps Research Institute) With the heightened concerns over the dangerous side effects of the once-popular antidiabetic drug Avandia, researchers at The Scripps Research Institute (TSRI) in Jupiter, Florida, are working to understand how small molecules, like those in Avandia, can have such varied effects throughout the body. The insights could help researchers design new drugs with better efficacy and fewer side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2017 Category: International Medicine & Public Health Source Type: news

FDA Drug Safety Communication: Reminder to healthcare providers and patients to enroll in the Avandia-Rosiglitazone Medicines Access Program
[11-04-2011] The U.S. Food and Drug Administration (FDA) is reminding healthcare providers and patients about the need to enroll in the Avandia-Rosiglitazone Medicines Access Program by November 17, 2011 in order to continue prescribing and receiving rosiglitazone-containing medicines (Avandia, Avandamet, and Avandaryl). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines
The U.S. Food and Drug Administration (FDA) has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and generics, do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines metformin and sulfonylurea. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

rosiglitazone, Avandia
Title: rosiglitazone, AvandiaCategory: MedicationsCreated: 11/28/1999 12:00:00 AMLast Editorial Review: 5/15/2017 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - May 15, 2017 Category: Endocrinology Source Type: news

Taking Aim At The Opioid Industry
Late last year, the Associated Press combined reporting with the Center for Public Integrity to roll out a multi-part series on the $880 million spent on lobbying and political contributions by the opioid industry in a decade long effort to stymie efforts to control these powerful drugs. Reporters reviewed of hundreds of documents brought to light in a recent court case and interviewed over 200 officials, experts, and advocates to understand how the opioid epidemic unfolded. The series had its genesis when the AP’s Matthew Perrone tripped across a group called the Pain Care Forum. Led by the top lobbyist for Purdue P...
Source: Healthy Living - The Huffington Post - March 7, 2017 Category: Consumer Health News Source Type: news

Avandia (Rosiglitazone Maleate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 3, 2017 Category: Drugs & Pharmacology Source Type: news

Avandaryl (Rosiglitazone Maleate and Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2016 Category: Drugs & Pharmacology Source Type: news

Avandamet (Rosiglitazone Maleate and Metformin HCl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 18, 2016 Category: Drugs & Pharmacology Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Avandamet (rosiglitazone/metformin)
Title: Avandamet (rosiglitazone/metformin)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 9/21/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 21, 2016 Category: Endocrinology Source Type: news

3 Drugs with the Most Severe Side Effects
Image Source Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever. The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 20, 2016 Category: Consumer Health News Source Type: news

La FDA elimina la Estrategia de Evaluación y Mitigación de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está eliminando la Estrategia de Evaluación y Mitigación de Riesgos (REMS por sus siglas en inglés) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que están aprobados como Avandia, Avandamet, Avandaryl y los genéricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news

La FDA elimina la Estrategia de Evaluaci ón y Mitigación de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está eliminando la Estrategia de Evaluación y Mitigación de Riesgos (REMS por sus siglas en inglés) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que están aprobados como Avandia, A vandamet, Avandaryl y los genéricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news

La FDA elimina la Estrategia de Evaluaci ó n y Mitigaci ó n de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administraci ó n de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en ingl é s) est á eliminando la Estrategia de Evaluaci ó n y Mitigaci ó n de Riesgos (REMS por sus siglas en ingl é s) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que est á n aprobados como Avandia, Avandamet, Avandaryl y los gen é ricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Follies, Part 2
Part 1 of this series appeared just over a year ago (in a different publication), and detailed a few of the agency's recent missteps. Prominently mentioned was the sad case of certain diabetes meds, including Actos, once touted as a safer alternative to Avandia. Avandia was taken off the market in 2011, but reappeared subject to severe limitations of use. These limitations were later removed—although current usage of the drug is small. Oddly, Actos (FDA approved in July, 1999) was showing some problems (bladder cancer) as early as 2005, even though this information was not widely disseminated at the time. Some migh...
Source: Healthy Living - The Huffington Post - May 17, 2016 Category: Consumer Health News Source Type: news

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients
[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 8, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Reminder to healthcare providers and patients to enroll in the Avandia-Rosiglitazone Medicines Access Program
[11-04-2011] The U.S. Food and Drug Administration (FDA) is reminding healthcare providers and patients about the need to enroll in the Avandia-Rosiglitazone Medicines Access Program by November 17, 2011 in order to continue prescribing and receiving rosiglitazone-containing medicines (Avandia, Avandamet, and Avandaryl). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 1, 2016 Category: Drugs & Pharmacology Source Type: news

Pioglitazone, Not Rosiglitazone, Again Tied to Bladder CancerPioglitazone, Not Rosiglitazone, Again Tied to Bladder Cancer
"Substantial and fairly consistent" evidence points to pioglitazone as associated with increased risk of bladder cancer, and this study strengthens and "confirms" that evidence, an expert says. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Diabetes drug linked to increased bladder cancer risk
Conclusion It seems likely from this research that pioglitazone is linked to an increased risk of bladder cancer, although the overall chances of getting bladder cancer remain very low. While this type of research cannot prove that pioglitazone is the cause of the increased risk of bladder cancer, it is not easy to find a convincing alternative explanation for these results. Previous research has already shown unexpectedly higher levels of bladder cancer among people taking pioglitazone, although other studies had found no such link. However, the size and the care with which this new study was carried out makes it convinc...
Source: NHS News Feed - March 31, 2016 Category: Consumer Health News Tags: Cancer Diabetes Medication Source Type: news

FDA Statement on Avandia TIDE Trial
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2016 Category: Drugs & Pharmacology Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: FDA requiere que se eliminen ciertas restricciones al recetar y dispensar medicamentos para la diabetes que contienen rosiglitazona
El 25 de noviembre, 2013, La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) ha determinado que datos recientes sobre medicamentos que contienen rosiglitazona, como Avandia, Avandamet, Avandaryl y versiones genéricas, no indican un riesgo mayor de ataque al corazón en comparación con los medicamentos estándar metformina y sulfonilurea para la diabetes de tipo 2. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines
The U.S. Food and Drug Administration (FDA) has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and generics, do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines metformin and sulfonylurea. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

REMS No Longer Necessary for Rosiglitazone-Containing Diabetes Drugs (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM The Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 17, 2015 Category: Primary Care Source Type: news

FDA Lifts Final Regulatory Restrictions on RosiglitazoneFDA Lifts Final Regulatory Restrictions on Rosiglitazone
The FDA pulls the plug on its prior risk evaluation and mitigation strategy for rosiglitazone-containing type 2 diabetes medicines. News Alerts (Source: theHeart.org)
Source: theHeart.org - December 16, 2015 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Lifts Restriction On Rosiglitazone
(MedPage Today) -- Agency sees no need for restrictions after easing them 2 years ago (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 16, 2015 Category: Cardiology Source Type: news

Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication - FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS)
The REMS is no longer necessary to ensure that the benefits of rosiglitazone medicines outweigh their risks. (Source: FDA MedWatch)
Source: FDA MedWatch - December 16, 2015 Category: American Health Source Type: news

A New Approach to Revolutionize Clinical Trials
It may be the biggest thing in medicine in a long time. It's not a new drug, or therapy or discovery. Instead it's a new way of doing clinical trials which could have a dramatic effect, particularly on those diseases that get less attention. Initially it is aimed at the deadliest brain cancer, glioblastoma multiforme, known as GBM. From diagnosis, it can kill in about six months. Traditionally clinical trials test one drug or a therapy on a lot of patients, sometimes thousands, against a control group that is treated with a placebo, or not treated at all. Trials drag on for years. The aim in clinical trials, which are cert...
Source: Science - The Huffington Post - December 8, 2015 Category: Science Source Type: news

New adipogenic cocktail that produces functional adipocytes from mesechymal stromal cells
Multipotent mesechymal stromal cells (MSCs) have been recognized as a source of adipocytes both in vivo and in vitro. It is reported that, simultaneous activation of canonical signaling pathways by dexamethasone through the glucocorticoid receptor and CCAAT-enchancer-binding proteins (C/EBPs) and rosiglitazone through peroxisome proliferator-activated receptor gamma (PPAR-gamma), is sufficient for inducing adipogenic differentiation from MSCs, producing functional adipocytes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 8, 2015 Category: Science Source Type: news

Avandamet (rosiglitazone/metformin)
Title: Avandamet (rosiglitazone/metformin)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 8/20/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - August 20, 2015 Category: Endocrinology Source Type: news

Ubc9 Enzyme Eyed as Potential Target for Diabetes Therapy
(MedPage Today) -- Inhibiting Ubc9 may boost potency of diabetic meds like rosiglitazone (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 9, 2015 Category: Cardiology Source Type: news

Common Diabetes Meds Tied to Lower Risk for Parkinson's
Study can't prove cause and effect, but saw dip in odds for people taking drugs such as Actos and Avandia (Source: WebMD Health)
Source: WebMD Health - July 22, 2015 Category: Consumer Health News Source Type: news

Common Diabetes Meds Tied to Lower Risk for Parkinson's
Study can't prove cause and effect, but saw dip in odds for people taking drugs such as Actos and Avandia Source: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Parkinson's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 21, 2015 Category: Consumer Health News Source Type: news